BHWA
RIGL icon

Beacon Harbor Wealth Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History

Beacon Harbor Wealth Advisors’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-152,133
Closed -$4.31M – 80
2025
Q3 		$4.31M Buy
+152,133
New +$4.55M 1.01% 44

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Beacon Harbor Wealth Advisors's RIGL Position: Q4 2025 in Review

Beacon Harbor Wealth Advisors sold out of Rigel Pharmaceuticals (RIGL) in Q4 2025, closing a stake of 152,133 shares — an estimated $4.31M sold.

Beacon Harbor Wealth Advisors first reported a position in RIGL in Q3 2025 and held it in 1 quarter. The position peaked at $4.31M in Q3 2025. 193 funds tracked by Wall St. Rank hold RIGL as of Q4 2025.

  • Beacon Harbor Wealth Advisors reported no remaining Rigel Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Beacon Harbor Wealth Advisors sold 152,133 Rigel Pharmaceuticals shares in Q4 2025, an estimated $4.31M.
  • Beacon Harbor Wealth Advisors first reported a position in Rigel Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Beacon Harbor Wealth Advisors's Rigel Pharmaceuticals position peaked at $4.31M in Q3 2025.
  • 193 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2025.

Based on Beacon Harbor Wealth Advisors's 13F filing for Q4 2025, filed 23 Jan 2026.